Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.
BACKGROUND: Chronic heart failure (CHF) is a major cause of morbidity and mortality that requires a novel approach to therapy. Perhexiline is an antianginal drug that augments glucose metabolism by blocking muscle mitochondrial free fatty acid uptake, thereby increasing metabolic efficiency. We asse...
Main Authors: | Lee, L, Campbell, R, Scheuermann-Freestone, M, Taylor, R, Gunaruwan, P, Williams, L, Ashrafian, H, Horowitz, J, Fraser, A, Clarke, K, Frenneaux, M |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2005
|
Similar Items
-
Augmentation of glucose metabolism with perhexiline in non-ischaemic heart failure
by: Lee, L, et al.
Published: (2004) -
Perhexiline.
by: Ashrafian, H, et al.
Published: (2007) -
Effects of perhexiline on ketone body and triglyceride synthesis in patients with refractory angina or heart failure
by: Shivu, G, et al.
Published: (2008) -
Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy.
by: Abozguia, K, et al.
Published: (2010) -
Metabolic Modulation With Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic Cardiomyopathy
by: Abozguia, K, et al.
Published: (2009)